Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

Inclusion Criteria: * Male or female, age 18 to 75 * BMI ≥ 25.0 kg/m2 \< 36.0 kg/m2 * HbA1c ≥ 7.5% and ≤ 10.5% * Type 2 Diabetes Mellitus and on stable dose of Metformin. Patients must have been on a stable dose of oral metformin (at least 1000 mg/day) for a minimum of 3 months prior to screening evaluation and will be required to continue their stable dose of metformin throughout the study. Patients on a stable dose of metformin plus a sulfonylurea (SU) or metformin plus a dipeptidyl peptidase-IV (DPPIV) inhibitor for a minimum of 3 months prior to Screening evaluation may be allowed * Agree to conduct home-based (fasted) blood glucose testing as directed Exclusion Criteria: * Clinically significant abnormalities in medical history or physical exam * Show evidence of uncorrected hypothyroidism or hyperthyroidism * History of liver transplantation or renal dialysis * History of liver disease * History of greater than 3 episodes of severe hypoglycemia within 6 months of screening * Treatment with any other antidiabetic drug(s) other than metformin, SU or DPPIV within 3 months of screening * History of diabetic ketoacidosis * Any other significant illness or condition that may interfere with the patient participating or completing the study * Inability or unwillingness to comply with protocol or study procedures -